SCHEMBL5594626

SCHEMBL5594626

Oc1ccc(CN2CCOCC2)c2cccnc12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.75
MAPT P10636 9/20 0.75
L3MBTL1 Q9Y468 9/20 0.75
LMNA P02545 5/20 0.75
NFKB1 P19838 4/20 0.75
NFKB2 Q00653 4/20 0.75
RELA Q04206 4/20 0.75
TP53 P04637 4/20 0.75
GAA P10253 4/20 0.75
ALOX12 P18054 4/20 0.75
ALDH1A1 P00352 4/20 0.75
BRD4 O60885 2/20 0.75
USP2 O75604 1/20 0.70
ALOX15 P16050 1/20 0.70
NPC1 O15118 3/20 0.67
RAB9A P51151 3/20 0.67
PAX8 Q06710 1/20 0.67
METAP2 P50579 1/20 0.64
SMN1; SMN2 Q16637 7/20 0.62
HTT P42858 5/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2518179 0.90 KDM4E (0.86) KDM4EMAPTL3MBTL1LMNANFKB1
Hydrochloric Acid SCHEMBL5594620 0.88 KDM4E (0.83) KDM4EMAPTL3MBTL1LMNANFKB1
SCHEMBL24716091 0.87 KDM4E (0.97) KDM4EMAPTL3MBTL1LMNANFKB1
SCHEMBL30626619 0.87 KDM4E (0.97) KDM4EMAPTL3MBTL1LMNANFKB1
SCHEMBL5594386 0.86 KDM4E (1.00) KDM4EMAPTL3MBTL1LMNANFKB1
SCHEMBL5594566 0.86 KDM4E (0.89) KDM4EMAPTL3MBTL1LMNANFKB1
SCHEMBL23714056 0.85 L3MBTL1 (0.59) KDM4EMAPTL3MBTL1LMNANFKB1
SCHEMBL17223775 0.84 L3MBTL1 (0.58) KDM4EMAPTL3MBTL1LMNANFKB1
SCHEMBL1240789 0.84 L3MBTL1 (0.80) KDM4EMAPTL3MBTL1LMNANFKB1
SCHEMBL5594558 0.83 KDM4E (0.75) KDM4EMAPTL3MBTL1LMNANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1189606-B1 NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS YEDA RES & DEV (IL) 2007-08-15 EP claimed
US-6855711-B1 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2005-02-15 US claimed
EP-4623914-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-10-01 EP disclosed
EP-4622962-A1 SMALL MOLECULAR WEIGHT CHEMICAL COMPOUND TO ANTAGONIZE EPH-EPHRIN TETRAMERIZATION AND INHIBIT BIDIRECTIONAL SIGNALING The Board of Regents of the University of Texas System (US) 2025-10-01 EP disclosed
CN-120035438-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2025-05-23 CN disclosed
US-20240246916-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-07-25 US disclosed
WO-2024109684-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE 江苏亚虹医药科技股份有限公司 2024-05-30 WO disclosed
CN-118059101-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2024-05-24 CN disclosed
WO-2024092083-A1 SMALL MOLECULAR WEIGHT CHEMICAL COMPOUND TO ANTAGONIZE EPH-EPHRIN TETRAMERIZATION AND INHIBIT BIDIRECTIONAL SIGNALING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-05-02 WO disclosed
WO-2024092083-A1 SMALL MOLECULAR WEIGHT CHEMICAL COMPOUND TO ANTAGONIZE EPH-EPHRIN TETRAMERIZATION AND INHIBIT BIDIRECTIONAL SIGNALING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-05-02 WO disclosed
EP-4349815-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2024-04-10 EP disclosed
US-10905682-B2 Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease CORNELL UNIVERSITY (US) 2021-02-02 US disclosed
US-20180360815-A1 USE OF MITOCHONDRIAL IRON CHELATORS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-12-20 US disclosed
EP-3383415-A1 USE OF MITOCHONDRIAL IRON CHELATORS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Cornell University (US) 2018-10-10 EP disclosed
WO-2017096013-A1 USE OF MITOCHONDRIAL IRON CHELATORS FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE CORNELL UNIVERSITY (US) 2017-06-08 WO disclosed
EP-1189606-B1 NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS YEDA RES & DEV (IL) 2007-08-15 EP disclosed
EP-1189606-B1 NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS YEDA RES & DEV (IL) 2007-08-15 EP disclosed
US-6855711-B1 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2005-02-15 US disclosed
EP-1189606-A2 NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) 2002-03-27 EP disclosed
WO-2000074664-A2 NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2000-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246916-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF CYP3A7, UGT1A7, UGT2B7 KDM4E 2921/4885MAPT 4416/4885L3MBTL1 3845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.